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medicine. The call for evidence in any part of medical
practice is nowadays stronger than ever. In contrast,
however, to what happened with carotid endarterec-
tomy, the rapid increase in the performance of which
followed the publication of the randomised trials, the
endovascular revolution in the treatment of abdominal
aortic aneurysms (AAAs) has preceded the publi-
cation of the results of the EVAR and the DREAM
trials.1–5 The support and feedback for this revolution
have been provided, to a large extent, by large-scale
multicenter registries, the data of which have proved
to be invaluable in various aspects.
First of all, registries have been well ahead of
randomised trials due to their ability to collect data
quickly and efficiently. With more than 7000 patients
entered by the end of 2004, EUROSTAR represents the
largest registry of EVAR today,6–9 with the RETA registry
following with an also impressive number of 1823
endovascular procedures.10,11 In comparison, the EVAR
trial 1 included 543 patients in its endovascular arm1,4 and
DREAM 173.2,5 The large number of patients in registries
has enabled numerous secondary analyses, while trials
are not sufficiently powered to allow ad hoc comparisons
between subgroups, e.g. comparisons between endo-
vascular aneurysm repair (EVAR) and open repair in
patients with inflammatory aneurysms, identification of
the risk factors for early or late conversion etc.
It should also be noted that registries can give a
more complete picture of the patient population to be
treated as well as of the range of methods and
materials that may be employed since they have no
restrictions posed by a trial protocol. Similarly, the
reported results are more realistic as they are obtained
in a cross-section of clinical institutions with various
degrees of experience, working under routineng author. Christos D. Liapis, 131, Vas Sofias Ave.,
, Greece.
: liapis@med.uoa.gr
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were invited by the DREAM and the EVAR trials, i.e.
centres which had done at least 5 or 20 EVAR
procedures, respectively,1,2 whereas EUROSTAR
included 135 centres, some of which even reported
their first endovascular case.
Another useful application of registries is that the
information obtained from them has assisted clinical
investigators in designing randomised trials. Indeed,
registries have been the source of questions clinical
trials engaged to answer convincingly. Since the late
1990s, registries have pointed out the low periopera-
tive mortality of EVAR in patients considered fit for
open surgery (2.3–4% for patients in ASA I–III cate-
gories),6,10 the considerable mortality in unfit patients
(12.5–18% for patients in ASA IV–V categories)6,10 as
well as the problems of durability and long-term
efficacy of EVAR (3% risk of late failure per year with
the use of first and second-generation devices).7 EVAR
trial 1 and DREAM have recently confirmed that
EVAR reduces the 30-day operative mortality in fit
patients by two thirds compared with open repair,1,2
while the EVAR trial 2 has demonstrated that EVAR
does not improve survival over no intervention in
patients already unfit for open repair of their
aneurysm.3 The mid-term efficacy of EVAR is still a
matter of debate.4,5
Registries have also made some important contri-
butions to the evolution of endovascular devices. At
the time when most surgeons were unwilling to report
bad results with EVAR, registries pointed out the
specific problems encountered during follow-up.5,7
Graft migration was identified and led to the manu-
facture of stent-grafts with improved fixation mech-
anisms. Graft kinking resulting from contraction of the
sac in its longitudinal dimension was also reported,
leading to the construction of stent-grafts with
increased kink resistance. Fabric tear, hook fracture,
limb disarticulation and suture breakage were alsoEur J Vasc Endovasc Surg 30, 341–342 (2005)
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and stronger graft designs. EUROSTAR has recently
verified that the use of current devices has improved
the mid-term outcome of EVAR, halving the need for
secondary transfemoral intervention and significantly
reducing conversion to open repair and aneurysm-
related death.8
Another potential application of registries, though
not yet exploited, is that they can serve as an audit tool,
monitoring the degree to which vascular surgeons are
managing AAAs in accordance with the principles of
best clinical practice. Direct comparisons between the
morbidity and mortality of individual surgeons may
enable these surgeons to modify their practice
patterns. Similarly, data derived from international
registries may be used by health care administrators
and lead to changes in national health priorities and
strategies with regard to AAA repair. For example, an
important lesson learnt by the EUROSTAR registry is
that specialist teams with a high level of experience in
EVAR encounter lower mortality rates and fewer
adverse events leading to secondary interventions.9
Interestingly, the threshold of procedures needed to
minimise complications is very high in the case of
EVAR, maybe higher than 90 patients. Therefore,
EVAR should be centralised in units specialising in
the technique and with a sufficient number of
operations annually to optimise the results.
The educational function of registries should also be
underscored. For rapidly evolving techniques, such as
EVAR, the information found in textbooks is already
out of date by the time these books reach the shelves.
Therefore, not only for students and residents, but also
for vascular specialists, registries can serve as an
excellent tool for continuous medical education,
providing a wealth of up-to-date clinical information.
Of course, several limitations and shortcomings of
registries should be acknowledged: selection bias due
to the voluntary nature of the registry; participation
only of enthusiastic, and thus more dedicated, surgical
teams; incomplete reporting; lack of a representative
control group to allow direct comparisons with open
surgery; and in addition to these drawbacks, registries
heavily subsidized by the industry are lacking
objectivity and are not included in the levels of
evidence list.12 On the other hand, registry data have
proved to be valid, truly reflecting a representative
cross-section of patients, methods and hospitals.
Information derived from registries is therefore
invaluable for the surgeon, the resident, the researcher,
the industry as well as the health care administrators.
It is therefore, imperative that the registries be
conducted either by national authorities or at least
under the guidance of well-respected scientific bodiesEur J Vasc Endovasc Surg Vol 30, October 2005such as the European Society for Vascular Surgery
(ESVS). Owing to the heavy financial demands of
conducting large-scale registries, financial support
should be requested upon explaining to the authorities
that the existence of a well-structured and well-
operated registry on a European level, for such issues
as endovascular treatment of aneurysms, is to the
benefit of the patients, the scientific community as a
whole and finally to the tax-payer.References
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